prednisone has been researched along with niraparib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E | 1 |
| Attard, G; Chi, KN; Diorio, B; Efstathiou, E; Francis, P; Lee, JY; Lopez-Gitlitz, A; Mason, GE; Olmos, D; Pereira de Santana Gomes, AJ; Rathkopf, D; Roubaud, G; Saad, M; Sakalo, V; Sandhu, S; Small, EJ; Smith, MR; Wang, G; Wu, D; Zurawski, B | 1 |
| Chi, KN; Chiuri, VE; Daksh, M; De Porre, P; Fleshner, N; Hafron, J; Mason, GE; Maul, RS; McNeel, DG; Tutrone, RF; Van Bruwaene, S; Zhong, X | 1 |
| Bjartell, A; Sjöström, M | 1 |
| Barthélémy, P; Bischoff, H | 1 |
| Attard, G; Castro, E; Chi, KN; Del Corral, A; Dibaj, S; Diorio, B; Efstathiou, E; Francis, P; Gurney, H; Jung, W; Kim, W; Mason, GE; Olmos, D; Pereira de Santana Gomes, AJ; Rathkopf, DE; Roubaud, G; Saad, M; Sandhu, S; Small, EJ; Smith, MR; Urtishak, K; Wu, D | 1 |
4 trial(s) available for prednisone and niraparib
| Article | Year |
|---|---|
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Middle Aged; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thiohydantoins | 2021 |
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Recombinational DNA Repair; Treatment Outcome | 2023 |
2 other study(ies) available for prednisone and niraparib
| Article | Year |
|---|---|
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Piperidines; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
[New drug approval: Fixed dose association of niraparib and abiraterone acetate in metastatic castration resistant prostate cancer with BRCA1/2 mutation].
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Drug Approval; Humans; Male; Mutation; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |